IndustryCompany release

Alkermes third-quarter revenue rises to $480.1M as LUMRYZ sales lift top line

🇺🇸 Alkermes plc. (ALKS) · Tue 03 Nov 2026

Alkermes reported higher third-quarter 2026 revenue on LUMRYZ sales after the Avadel transaction, while GAAP net income was $16.3 million, and it left its 2026 financial expectations unchanged.

Alkermes plc reported third-quarter 2026 results on 3 November, with total revenue of $480.1 million, up from $394.2 million in the same quarter a year earlier.

The company attributed part of the increase to LUMRYZ, which contributed $89.9 million in sales following the Avadel transaction.

GAAP net income for the quarter was $16.3 million. Adjusted EBITDA was $120.1 million. Alkermes kept its financial expectations for 2026 unchanged.

On its pipeline, the company pointed to progress in its orexin 2 receptor agonist programmes. It cited proof-of-concept data in attention deficit hyperactivity disorder (ADHD) and a new phase 2 study in major depressive disorder. The summary provided does not give further detail on the data or the study design.

What it means for your team

  • The Avadel transaction has added a commercial product, LUMRYZ, to Alkermes' revenue base, which is relevant for teams tracking the company's portfolio and market position.
  • Unchanged 2026 financial expectations suggest no change to the company's near-term outlook, according to the results summary.
  • The new phase 2 study in major depressive disorder extends the orexin 2 receptor agonist programmes beyond ADHD, a development for pipeline and market-access watchers to monitor.

Company's press release (SEC filing): Alkermes plc. ↗

Article written by VigiEye from the official source (Alkermes plc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →